Gavi 2016–2020

What the Vaccine Alliance

can achieve together in

the next five-year period

1 #vaccineswork

Gavi/2011/D

oune

Port

er

THE ASK FOR 2016–2020

2 #vaccineswork

US$ 7.5 billion

additional funding

needed for immunisation

programmes through to 2020

Gavi/2013/A

ssad Z

aid

i

(US$ billion)

ACCELERATING IMPACT 2016–2020

With US$ 7.5 billion over 5 years:

3

Fully protected

children increase

from 5% to 50%

Economic

benefits total

US$ 80–100 billion

#vaccineswork

GAVI, THE VACCINE ALLIANCE, 2016–2020

Protect past investments and pave the way to sustainability

4

all countries

co-financing

22 graduatedcountries

strengthening

health systems

transforming

vaccine markets

#vaccineswork

US$ 7.5 billion over

5 yearswill help to achieve

all this

CLOSING THE IMMUNISATION GAP

Vaccine coverage in Gavi-supported countries by 2020

5

a 2012 coverage estimates are based on country official reported figures.

b Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in

Africa.

c Target population for HPV3 is 9-13 year old girls, 2012 coverage estimates derived from SDF projections

about scale-up.

Sources: 2012: WHO/UNICEF coverage estimates and country official reported figures (MCV2 and rubella),

as of July 2013. 2015 and 2020 coverage: Gavi Strategic Demand Forecast version 9.

#vaccineswork

50% OF CHILDREN IN GAVI-SUPPORTED COUNTRIES FULLY IMMUNISED BY 2020

Immunisation coverage in Gavi-supported countries (%)

6

Source: Preliminary Gavi projections based on WHO/UNICEF coverage estimates and Strategic Demand

Forecast version 9.

Fully immunised

children (73 Gavi-

supported countries)

#vaccineswork

BEYOND CO-FINANCING NEW VACCINES

Increasing domestic expenditure on immunisation

7

Source: Preliminary findings from Johns Hopkins and GVAP Steering Committee (2014), Costing, Financing,

Gap, and Return on Investment Analysis for Global Vaccine Action Plan (GVAP).

2011-2015

US$ 8 billion

2016-2020

US$ 12 billion

2011-2015

US$ 0.47 billion

2016-2020

US$ 1.2 billion

Gavi co-financing

Total domestic investments in immunisation

+250%

+50%

#vaccineswork

ECONOMIC BENEFITS OF IMMUNISATION

in Gavi-supported countries, 2016–2020

8

5–6millionlives saved

+100millionillness cases averted

80–100US$ billioncosts averted

related to illness:

• productivity loss due

to death/disability

• treatment costs

• caretaker productivity loss

• transport costs

Sources: Update using methods from 1) Lee LA et al. The estimated mortality impact of vaccinations forecast

to be administered during 2011–2020 in 73 countries supported by Gavi. Vaccine 2013; 2) Stack M et al.

Estimated economic benefits during Decade of Vaccines, Health Affairs 2011.

#vaccineswork

Gavi/2012/S

ala

Lew

is

EFFICIENCY

9 #vaccineswork

97% of Gavi expenditure directly supports programmes,

2016–2020

(US$ billion)

WHAT WE WILL ACHIEVE TOGETHER

10 #vaccineswork

additional children immunised of total number of children

immunised in the world

=

2016–2020

WHAT WE WILL ACHIEVE TOGETHER

11 #vaccineswork

Prevent more

future deaths

than children

born in the EU

every year

2016–2020

Gavi/2013/E

vely

n H

ockste

in